<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323724</url>
  </required_header>
  <id_info>
    <org_study_id>2014/617</org_study_id>
    <nct_id>NCT02323724</nct_id>
  </id_info>
  <brief_title>APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.</brief_title>
  <official_title>APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <brief_summary>
    <textblock>
      To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E
      BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V
      of Bethesda System)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study To determine the improvement in diagnosis of papillary carcinoma by
      detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis
      (categories III, IV and V of Bethesda System).

      Design: Retrospective observational study. Scope: The study will be peformed at the Pathology
      Service, from cytological samples and paraffin file post-diagnosis. Mutations are detected by
      pyrosequencing technique.

      Subject of study:

      Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological
      diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in
      Corporació Parc Taulí.

      Methodology:

        -  Identification of cases

        -  Detection of BRAF V600E mutation, initially in histological material from the surgical
           specimen, and if present, detection in cytological material.

      The statistical analysis will use SPSS. Univariate and bivariate analysis will be done.
      Results will be presented in the form of frequency tables and percentages for qualitative
      variables and by average, median and standard deviation for quantitative variables. Pearson
      chi-square or Fisher's exact test will be applied. The Student t test or the Mann-Whitney
      test will be performed for quantitative variables.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in diagnosis</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V of Bethesda System).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Papillary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Selected Papillary carcinoma</arm_group_label>
    <description>Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>BRAF V600E mutation by pyrosequencing technique</intervention_name>
    <arm_group_label>Selected Papillary carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological
        diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in
        Corporació Parc Taulí
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological
             diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July
             2014 in Corporació Parc Taulí

        Exclusion Criteria:

          -  Non available cytological or histological material
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Rosa Bella Cueto</investigator_full_name>
    <investigator_title>Coordinator of Pathology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

